Medical Device Weekly Highlights (May 25–31, 2026): Funding, Approvals, M&A, and Global Expansions

Recently, Neuraic, a hard-tech startup focused on the clinical translation of brain-computer interfaces (BCI) and led by Dr. Gu Huidong, completed a tens-of-millions-yuan angel financing round. The round was led by Enran Venture Capital, with participation from Hangzhou Runmiao Fund and West Lake Photonics, and co-investment from Shanghai Angel Club. Behind this rush of capital lies a formidable technological moat. Neuraic has industrialized twenty years of technical accumulation from the Institute of Semiconductors, Chinese Academy of Sciences, overcoming two major hurdles in the field of invasive BCIs: excessive trauma from flexible electrode implantation and rapid signal decay within a short period. Its self-developed semiconductor hollow flexible electrodes, combined with a proprietary "physiological saline rigid adjustment" process and a 13-micron-level minimally invasive implantation pathway, have achieved dual breakthroughs in animal models: a 70% reduction in acute injury and stable neural signals sustained for six months.

ROBO Medical, the company behind the approved digestive endoscopic surgical robot, has officially announced the successful completion of a financing round amounting to tens of millions of RMB. The round was led by Shuimu Ventures, with strategic investor Boyue Tiancheng participating, and Siche Consulting serving as the exclusive long-term financial advisor. The funds raised will be primarily allocated to the nationwide clinical deployment of its core product, the EndoFaster® (Su Yi Bi) digestive endoscopic surgical robot; the research and development of its next-generation product, EndoDreams; the construction of an intelligent manufacturing base and supply chain optimization; as well as international market certification and hospital adoption promotion.

Lifetech Scientific Acquires Approximately 96.46% Equity Stake in Starway Medical for RMB 1.87 BillionLifetech Scientific, a company specializing in the research and development of interventional devices for cardiovascular, cerebrovascular, and peripheral vascular applications, has acquired approximately 96.46% of the equity interest in Starway Medical for RMB 1.87 billion. Lifetech Scientific reported revenue of RMB 1.37 billion in 2025. While its structural heart disease business experienced a decline, its peripheral vascular business became a key growth driver, although its vena cava filters were included in the volume-based procurement program.Starway Medical focuses on vascular interventional devices and possesses four core occluder products, with over 220,000 cumulative clinical implantations. The acquisition of Starway Medical will fill Lifetech Scientific’s gap in patent foramen ovale (PFO) occluders. Given the substantial potential market size for PFO occluders in China, this acquisition will provide Lifetech Scientific with mature products and strengthen its structural heart disease product portfolio.Starway Medical is effectively controlled by Hillhouse Capital. This transaction does not involve cash payments. Following the merger, Lifetech Scientific will integrate resources and optimize its strategic layout, which is expected to unlock new growth opportunities.

Recently, Shenzhen Ruixin Intelligent Medical Technology Co., Ltd. completed a Series D financing round of nearly RMB 100 million, led by Guangzhou Health Industry Investment and followed by Yuefu Fund, with its operations established in Yuexiu District, Guangzhou. This financing round demonstrates recognition of Ruixin Medical’s core technologies, industrial value, and commercialization progress, and will inject momentum into the company’s overall pipeline development, business growth, and expansion into overseas markets. Following this financing, Ruixin Medical will deepen its layout of AI-driven vascular interventional surgical robot systems and build an integrated AI + robotics diagnosis and treatment platform. The company focuses on precise cardiovascular diagnosis and treatment and has built an integrated intelligent diagnostic and therapeutic platform. Its core product, AngioQFA, has become a benchmark for precise coronary artery diagnosis and treatment; Ruixin Fraction (CT-FFR) is continuously advancing clinical implementation; and its new deployment of intracardiac echocardiography (ICE) further completes the diagnostic and therapeutic closed loop. In the future, Ruixin Medical will continue to deeply cultivate the field of precise cardiovascular diagnosis and treatment.

On May 25, Medprin Regenerative Medical Technologies Co., Ltd. (“Medprin”), a leading domestic neurosurgical company, proposed to acquire 100% equity interest in Yijie Medical, a neurointerventional company, for RMB 335 million, thereby entering the high-growth neurointerventional sector. Established in 2020, Yijie Medical has a comprehensive pipeline of products under development and has built four major technology platforms. Medprin has long been deeply engaged in the neurosurgical field with stable performance growth; however, the growth potential of the neurosurgical medical device market is limited, and normalized volume-based procurement has narrowed profit margins. This acquisition will help Medprin expand its business into the neurointerventional field, strengthen strategic synergies, and integrate channel resources to broaden sales coverage. Medplin plans to leverage its biodegradable biomaterials technology platform, combined with trends in neurosurgical treatment, to develop therapeutic products for interventional procedures, with multiple projects currently planned for research and development. Furthermore, since the beginning of this year, mergers and acquisitions in China’s medical device market have continued unabated. For leading enterprises, entering new sectors or strengthening existing businesses through M&A has become an important strategic initiative.